Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals reports a Q1 2026 loss amid a cash outflow, yet a strategic Lifeward deal and POD™ tech transfer spark hope for future oral drug‑delivery growth.

Oramed Pharmaceuticals partners with Lifeward Ltd. to merge its Protein Oral Delivery (POD) platform into MedTech products, promising a new era for oral biologic drug delivery.